• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

What to Know if Your Doctor Put You on Statins to Lower Cholesterol
High cholesterol is a prime example of having too much of a good thing. Our bodies naturally make this substance in the liver and then transport it throughout the body for multiple functions, including hormone regulation, cell tissue regeneration, and vitamin absorption. When the system is working well, cholesterol can boost overall health. But when a certain type called low-density lipoprotein—LDL, sometimes dubbed the “bad” kind—is overproduced, not only does it block the “good” kind called high-density lipoprotein (HDL), but it can also begin to accumulate in the arteries and form thi...
Source: TIME: Health - January 25, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

If you could propose one idea to help improve health care delivery in the United States, what would it be?
Thumbnail: Tags: conversationsphrma conversationslarry hausnermyrl weinbergchris hansennancy brownContributors: 11621161115911631173Contributions: Read Larry Hausner's bio Despite the rapid development of innovative technologies in the health care field, we have yet to discover a panacea that will easily transform our health care system into one that provides high-quality and cost-effective care.  What we have discovered and come to agree on over the last decade is that our sick care system must be reconfigured to a health care system that emphasizes wellness and prevention.  For that reason, I offer ...
Source: PHRMA - June 24, 2013 Category: Pharmaceuticals Authors: rlowe Source Type: news

10 New Year ’s Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news

10 New Year's Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news